Down 34%, Should You Buy the Dip on Viking Therapeutics?
Key Points Viking Therapeutics (NASDAQ: VKTX) has intrigued investors over the past year and a half because it’s involved in a potential David and Goliath story. Today, pharma giants Eli Lilly and Novo Nordisk dominate the weight loss drug market, and other big pharmas such as Pfizer are working to get in on this valuable ...












